Headquartered in Crawley, West Sussex, Rapidcare is a family-owned UK dispensing appliance contractor, providing independent delivery of prescription medicines, medical devices, and related healthcare services.

The transaction builds on Rapidcare’s long-standing partnership with Qufora through its Qufora Direct service, enhancing the group’s presence in the UK medical supply market and supporting continued growth in patient care innovation.

The Kreston Reeves team was led by Partner Sarah Ediss and assisted by James O’Leary.

Sarah Ediss said: “We have had the pleasure of working with Rapidcare founders, Julia and Kevin Constable since 2013, helping them first acquire and then grow the business. It has been a privilege to support them on this sale. The family connection will not be lost, with Mark Constable, Julia and Kevin’s son, continuing to work with Qufora.”

“We are also excited to be working with other family members on the launch of a stunning new restaurant, Orla on Lindfield busy high street.”

Julia Constable, the founder and owner of Rapidcare, said: “This marks an exciting new chapter for Rapidcare, and I’m grateful to Kreston Reeves for its support and expert guidance throughout the process. While we have a longstanding partnership with Qufora, by joining forces more formally we can build on our strengths and continue delivering the high-quality, compassionate care our patients expect and deserve.”

DMH Stallard provided legal advice to Rapidcare and Addleshaw Goddard acting for Qufora. EMC Corporate Finance provided corporate finance advice.

This bold step cements Antalya’s position as both a tourism and medical destination. Since 2005, Dental Design Turkey has focused on merging digital innovation with aesthetic care, delivering not just treatment but an unforgettable experience.

“Using CE-certified European materials in all our treatments, we offer a 5-year guarantee on implants, crowns and veneers, a truly international guarantee,” says Cosmetic Dentist Dr. Gökhan Kökdere, Founding Partner at Dental Design Turkey.

Delivers not just treatment, but also confidence

Dental Design Turkey is committed to deepening its leadership in digital and aesthetic dentistry. In the upcoming period, the clinic plans to open representative offices around the world to strengthen its international patient relationships. The clinic is also investing in artificial intelligence and cutting-edge digital technologies to enhance precision and comfort in care.

“Our objective is to provide European-standard treatments in Türkiye as a solution to soaring costs and long waits elsewhere. By offering digitally supported treatments in shorter timeframes, we not only deliver first-class dental care to our patients particularly from the UK but we also ensure a fully trusted environment,” says Oral & Maxillofacial Surgeon Dr. Nesligül Niyaz Kökdere, Founding Partner at Dental Design Turkey.

“English-speaking patient coordinators accompany every patient throughout their journey. Trust and transparency are key in Türkiye’s health tourism success, and with that philosophy we deliver bespoke, ethical care to each patient from the UK.”

Restores healthy and confident smiles

For patients travelling from the UK, Dental Design Turkey combines clinical excellence, aesthetic vision and state-of-the-art technology under one roof. Through smile design and aesthetic dentistry, every patient receives results tailored to facial structure, expression and personal expectations. Using digital smile design tools, the clinic offers a preview of the final outcome — making the entire journey transparent from the outset

When it comes to implants, they replace missing teeth using long-lasting, biocompatible systems that satisfy both function and aesthetics. With zirconium veneers, the clinic applies a minimal-intervention approach to achieve maximum aesthetics. Addressing discolouration, misalignment and shape irregularities swiftly, they restore healthy, confident smiles.

Dental Design Turkey plans to launch professional training programmes under the umbrella of Dental Design Academy, attracting qualified specialists and supporting continuous innovation in the sector. In the long term, the clinic’s vision is to sustain Türkiye’s role as a globally trusted and premier destination in advanced dental healthcare.

About Dental Design Turkey

Dental Design Turkey is a state-of-the-art dental clinic located in Antalya, Türkiye. Since 2005, the clinic has specialised in digital dentistry, aesthetic treatments and patient-centric care. With an emphasis on quality, transparency and ethical standards, Dental Design Turkey integrates cutting-edge technology and expert clinical practice to serve both domestic and international patients. Its recent introduction of internationally guaranteed dental treatments, AI-driven approaches, and expansion through representative offices underscores its ambition to lead global dental tourism.

Dubai is now among the most reliable destinations in terms of aesthetic surgeries as they have the best facilities and stringent medical regulations. Aesthetics International Clinic is one of the few clinics that use modern technology with the medical skills to offer long lasting, natural and safe results. Also Check For Laser clinic in Dubai

The Science Behind Dermal Fillers

The Role of Hyaluronic Acid

The majority of dermal fillers in Dubai are based on hyaluronic acid – it is a substance that is naturally found in the human body. It makes the skin remain hydrated, elastic and youthful. As people get older, the natural supply of hyaluronic acid in the skin reduces resulting in skin drying up, wrinkling, and loss of volume.

Hyaluronic acid fillers, when injected by professionals, hold and draw water into the skin. This gives soft lift and support which makes the overall appearance fresher but does not change the face identity. The science behind it is how it replenishes the natural hydration system in the skin and supports collagen with greater benefits in the long run.

Filler Formulation Innovation

Modern filler products used in Dubai are more advanced than ever. They are designed according to various skin types, facial areas and the aesthetic desires such as soft hydration fillers on the sensitive under-eye areas and thicker volumizing fillers on cheeks and jawlines.

Only FDA-approved fillers of international medical brands are used in clinics including Aesthetics International Clinic. These formulas are purified, tested to be safe and biocompatible, so that they can blend with the natural tissues. Also Check For Breast Augmentation in Dubai

Safety First – Why Standards Matter in Dubai

Strict Medical Oversight

Dubai’s healthcare system operates under strong regulations set by the Dubai Health Authority (DHA) and the Ministry of Health. All the clinics that provide dermal fillers in Dubai should possess a proper hygienic level, use certified products, and trained practitioners.

This health care supervision instills confidence in the patient and reduces risks. The government’s emphasis on safety makes Dubai one of the safest global destinations for advanced aesthetic treatments.

Training and Technique

Even the finest filler will not work in the wrong hands. For that reason, Dubai’s top clinics focus on doctor training, anatomy-based injection techniques, and continuing education.

In Aesthetics International Clinic, the filler treatments are being done by board certified specialists, who are well experienced in facial anatomy. Their accuracy makes sure that the fillers are inserted in the right layers of skin in order to balance them and prevent problems with lumps or uneven outcomes.

Technology & Aesthetic Medicine

Image-Guided Assessments

The use of sophisticated imaging and mapping of the faces has altered the planning process of fillers. The facial analysis systems today make use of 3D analysis enabling doctors to see the result prior to the surgery. This aids the patients in knowing what they should expect and the final appearance is more balanced and natural. Also Check For Lips Fillers in Dubai

Doctors can also determine the amount of volume loss and various points that can be replenished in order to create a youthful effect without overcorrection using such tools.

Laser Therapy

Combination treatments are common in the use of modern dermal fillers in Dubai. To have a complete facial rejuvenation, clinics are combining fillers with laser treatment, collagen boosters or skin rejuvenation treatments.

These approaches complement each other – fillers can be used to regain the shape, whereas lasers and collagen applications can be used to enhance the texture and tone. They are all combined to create an entirely young look but not on single features but on the general health of the skin.

The Social and Psychological Aspect of Aesthetic Treatments

Although the main focus is on science and safety, it would be a mistake to disregard the emotional effect of fillers. Individuals commonly resort to fillers in an attempt to feel better and enhance their self-esteem as well as their appearance.

Aesthetic psychology studies have demonstrated little and natural boosts in mood, motivation, and self-esteem. Dubai, being a city where personal and professional image matters greatly, even minor gains can make a significant difference to self-esteem and welfare.

Aesthetics International Clinic is one of the clinics that understand this emotional aspect. The patient-focused healthcare that they provide focuses on honest communication, achievable objectives, and comfort in the process.

The Future of Dermal Fillers in Dubai

Dubai continues to set global standards in medical aesthetics. The demand for dermal fillers in Dubai is growing not only because of their beauty benefits but also due to the city’s focus on innovation and regulation.

The new developments are anticipated to involve longer-lasting fillers, bio-stimulatory compounds that induce natural collagen to develop and AI-based facial analysis to personalize it more accurately.

With the development of such technologies, safety and science will continue to form the core of the treatment – so that the effects are natural and predictable and can be sustained.

Reasons to Select Aesthetics International Clinic

Aesthetics International Clinic is among the top destinations in Dubai for professional filler treatments. The philosophy behind the clinic is straightforward, which is safety, precision and trust of the patients.

Their methods involve detailed consultations, FDA-approved products, and therapies that would be specific to the face structure of an individual. This is due to the expertise of the medical team, which provides results that do not overdo the natural beauty.

Such an approach to medical accuracy, craftsmanship, and patient-centered care is what makes the clinic a sure place to stay in case people care about their safety and appearance.

Conclusion

Dermal fillers in Dubai form the ideal combination of science, art and safety. Innovation, regulation, and professionalism have been the pillars that have enabled Dubai to become one of the safest destinations in the world where one can experience modern aesthetic care. 

Clinics such as Aesthetics International Clinic are still at the forefront of this change – providing reliable procedures to make natural beauty look even more beautiful with scientific certainty.

Having secured FDA 510(k) clearance and UKCA self-certification, Oxford Brain Diagnostics is now launching its commercial rollout across the UK and US, bringing cutting-edge brain health insights to healthcare providers and patients on a global scale.

Founded in 2019 by Dr Steven Chance (former Associate Professor of Neuroscience at Oxford University) and Professor Mark Jenkinson (Professor of Neuroimaging), Oxford Brain Diagnostics has built its technology on decades of expertise in brain pathology and imaging. The FDA recognised CDM’s potential in 2020 by granting Breakthrough Device Designation status for evaluating adults at risk of Alzheimer’s Disease.

In 2023 OBD secured a multi-million investment in a funding round led by BGF, the UK and Ireland’s most active growth capital investor, alongside continued support from its existing investors, including the Oxford Technology & Innovations Fund (OTIF). This crucial investment enabled OBD to achieve both FDA 510(k) clearance and UKCA self-certification, enabling the company to secure clinical rollout and establishing the regulatory foundation for global market expansion.

Dr Steven Chance, CEO & Co-Founder of Oxford Brain Diagnostics, commented: “Neurodegenerative diseases represent a growing public health challenge, impacting millions of patients and their families worldwide. The support from BGF and other investors and partners is enabling us to accelerate the path to the commercialisation of our software tool and bring hope to those millions who are seeking a non-invasive, precision diagnostic tool to reveal the truth about their brain health.”

Maggy Lau, Investor at BGF, added: “OBD’s progress over the past two years has been remarkable. The technology is truly differentiated, and its recent regulatory achievements signal just how close it is to making a major impact. We’re proud to back a business that’s taking on one of the toughest and most important challenges in healthcare today.”

The landscape for neurological diagnostics is evolving rapidly, particularly with the arrival of new anti-amyloid Alzheimer’s drugs sharpening the focus on early, accurate diagnosis. OBD’s technology directly addresses this by enabling timely detection and precise monitoring of neurodegenerative disease. The company has already achieved early traction working with pharmaceutical partners to support clinical trials and drug development, while simultaneously expanding into healthcare settings.

Beyond dementia, OBD’s platform shows promise in addressing other neurodegenerative conditions, including Parkinson’s Disease and Multiple Sclerosis, expanding its potential impact across clinical and research domains.

With its newly launched PA-100 AST System, Sysmex is pioneering a new standard in urinary tract infection diagnostics. Integrating advanced nanofluidic processes with rapid antimicrobial susceptibility testing (AST), the system delivers diagnostic clarity in just 45 minutes. This breakthrough empowers clinicians with accurate, data-driven insights in real time — enabling more effective, patient-specific care.

A global UTI crisis demands urgent innovation

Urinary tract infections affect over 400 million individuals worldwide each year, ranking among the most prevalent bacterial infections. Conventional diagnostic delays and empirical antibiotic use often lead to ineffective treatment and increased antimicrobial resistance (AMR). With sensitivity at 84% and specificity at 99%, the PA-100 AST System significantly improves diagnostic precision, helping reduce unnecessary prescriptions and curbing AMR.

Alain Baverel, President & CEO Sysmex Europe SE, remarked,
“The PA-100 AST System represents a pivotal innovation in the fight against antimicrobial resistance. By providing clinicians with rapid and precise diagnostic insights, we can transform how urinary tract infections are treated globally. This tool not only benefits patients but also strengthens the financial sustainability of healthcare systems.”

Spanish study points to multi-million euro savings

Recent budget modelling based on the Spanish healthcare system suggests the widespread adoption of the PA-100 AST System could lead to significant economic gains. Estimated savings of €323 million in the first year alone reflect reductions in hospital stays, secondary infections, and lost productivity. These benefits are expected to grow over a three-year horizon, signalling long-term value for national health services.

Takashi Ono, Member of the Managing Board and Senior Executive Officer & Managing Director of Sysmex Corporation, commented,
“By addressing one of the leading causes of antibiotic misuse, Sysmex’s PA-100 AST System aligns perfectly with global efforts to combat antimicrobial resistance. The system empowers healthcare providers with the data needed to make the right decision at the right time, benefiting patients and public health alike.”

Longitude Prize win highlights global impact

The PA-100 AST System’s innovation has not gone unnoticed. Last year, it received the prestigious Longitude Prize — a £8 million award recognising transformative technologies in the fight against AMR. This accolade underscores the system’s ability to make a tangible impact on both clinical practice and global health outcomes.

Compact, swift and highly effective

Housed within a cartridge no bigger than a smartphone, the PA-100 AST System identifies bacteriuria in just 15 minutes and determines suitable antibiotics within 30 more. Its speed reduces complications from delayed treatment, while its precision ensures patients receive the most appropriate care from the start.

Explore more about the PA-100 AST System

Following the lifting of a long-standing ban in 2021, the UK has been rebuilding its supply of plasma medicines amid a global shortage. The Government estimates that these treatments will help save 17,000 NHS patients’ lives each year.

Plasma is essential for people with blood cancer who rely on transfusions to manage infections. It is also used in emergency medicine, including childbirth and trauma care, making it a vital resource for the NHS.

]]> 139425 https://www.newsanyway.com/2025/03/06/o-concept-unveiled-at-harley-stree/ Thu, 06 Mar 2025 13:03:30 +0000 https://www.newsanyway.com/?p=139399 A leading Harley Street clinic has unveiled an innovative approach to sexual wellness, designed to enhance intimacy, confidence, and overall wellbeing.

Founded by Dr Sherif Wakil, TheOConcept.co.uk offers a comprehensive range of treatments tailored to address various sexual health concerns, providing bespoke solutions based on individual needs.

Recently recognised with a 2024 Global Excellence Award, the O Concept moves away from traditional and invasive treatments, instead focusing on a holistic and personalised approach to sexual health.

Unlike conventional treatments, which can affect hormones, impact mood, or even require surgery, this pioneering method combines advanced medical technologies with proven therapeutic techniques to support both men and women in achieving greater pleasure and confidence.

A Revolutionary Approach to Sexual Health

Dr Sherif Wakil, Founder of Dr SW Clinic, highlighted the importance of sexual wellness in overall health:

“We understand that sexual health is an integral part of overall well-being. Millions of men and women suffer from sexual dysfunction in the UK, deeply affecting their confidence, quality of life, relationships and even their ability to conceive.

“Such an overwhelming and complex issue requires a professional, advanced and carefully-tailored solution, which is exactly what the O Concept offers. It’s designed to provide individuals with the tools and resources they need to reclaim their sexual confidence and experience a more fulfilling intimate life.

“We offer personalised treatment plans, using state-of-the-art technologies including PRP and laser therapy, to stimulate tissue regeneration and enhance sensitivity, as well as integration of therapies to address physical and emotional aspects of sexual health.

“And with expert care provided by our team of medical professionals, clients can be assured of a safe and supportive environment.”

Personalised Treatments for Men and Women

The O Concept is designed to help individuals facing a range of sexual health concerns, including low libido, vaginal dryness, erectile dysfunction, painful intercourse, and difficulty achieving orgasm.

Among the specialist treatments available are:

• Scrotox – a wrinkle-relaxing treatment for the scrotum
• The O-Shot® – a PRP-based treatment to enhance orgasmic response
• G-Shot® – a G-Spot enhancement procedure
• Labia fillers – for aesthetic and functional improvements

With a focus on cutting-edge therapies and expert medical care, the O Concept aims to provide a discreet, professional, and supportive environment for clients seeking to improve their intimate health and confidence.

The Garfield Weston Foundation is one of the UK’s largest charitable trusts. Founded by the Weston family in 1958, it gives money to support a wide range of charities nationwide. In total, it donates around £100 million each year.

Laura Kerby, Chief Executive of Prostate Cancer UK, said: “We are absolutely thrilled that the Garfield Weston Foundation has become a Founding Partner of TRANSFORM through their £1m donation to Prostate Cancer UK.  This trial has the potential to change the landscape for men at risk of prostate cancer in the UK and globally, for generations to come.  We are honoured to be partnering with the Garfield Weston Foundation to make this a reality.”

Sophia Weston, Deputy Chair and Trustee at Garfield Weston Foundation, commented: “The Trustees are delighted to be collaborating with Prostate Cancer UK on this vital trial, bringing us closer to nationwide screening for prostate cancer.”

Led by world-leading researchers, TRANSFORM is designed to provide the definitive evidence needed to pave the way towards the best possible screening programme in the UK. It has been developed in consultation with the National Screening Committee and the National Institute for Health and Care Research (NIHR).

The six lead researchers for the TRANSFORM trial represent four of the UK’s biggest research centres and will work alongside 16 co-applicants from across the country:

• Professor Hashim Ahmed, at Imperial College London
• Professor Ros Eeles, at the Institute of Cancer Research, London
• Professor Mark Emberton, at University College London
• Professor Rhian Gabe, at Queen Mary University of London
• Professor Rakesh Heer, at Imperial College London
• Professor Caroline Moore, at University College London

The first stage of TRANSFORM will involve around 12,500 men and will compare four potential screening options, including fast MRI scans, genetic testing to identify men at high risk of prostate cancer, and PSA blood testing. This will take around three years, after which there will be significant new evidence. In the second stage, the researchers will test the most promising option – or options – from the first stage to see how well the screening method detects cancer and reduce harms to men. This will include up to 300,000 men and take around six years, following which the men involved in the study will be followed up for at least 10 years to see the longer-term impact of screening. Men will start to be invited to take part in the TRANSFORM trial in spring 2025.

Alongside the Garfield Weston Foundation, TRANSFORM’s other Founding Partners are the National Institute for Health and Care Research (NIHR), Movember, Omaze, Paddy Power and the Freddie Green and Family Charitable Foundation.

Nan Zhang received a $600,000 grant, marking the second V Foundation award for Wistar this year. The funding builds on a pilot study that identified interleukin one beta (IL1β), a protein linked to chemotherapy resistance in ovarian cancer. This grant will allow Zhang to take the first steps in developing potential anti-IL1β therapies to combat chemoresistant ovarian cancer.

Ovarian cancer is one of the most fatal cancers that affect women. While most patients with ovarian cancer respond to chemotherapy at first, the cancer can have potentially fatal consequences if it becomes resistant to treatment.

“This is an exciting opportunity to pursue a promising lead against a notoriously chemo-resistant cancer,” said Zhang. “The V Foundation has made this research project possible through their generosity; I look forward to reporting on what we find from our investigation.”

Dr. Noam Auslander was awarded a V Foundation grant earlier this year through the Women Scientists Innovation Award for Cancer Research, and she is an expert in machine learning and computational methods in cancer research. Her $600,000 grant funds a project aimed at improving immunotherapy responses in cancer patients. She and her team want to identify reliable “biomarkers” — accurate indicators of biological states — that could predict the trajectory of a patient’s response to a given immunotherapy treatment. Auslander believes such biomarkers could have the potential to improve clinical decision-making and treatment outcomes by tailoring therapy strategies for individual patients.

“We’re grateful to The V Foundation for the opportunity to launch this important project,” said Auslander. “We know from past experience that large datasets from the microbiome carry important information that can predict health outcomes; with this funding, we hope to find patterns that will predict — and therefore inform — responses to immunotherapy.”

The Phase 2a trial, titled EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of exidavnemab in Parkinson’s patients. Conducted in Europe, the trial will enroll at least 24 participants, divided into two cohorts of 12 patients each.

• Cohort 1: Receives either a lower dose of exidavnemab or placebo.
• Cohort 2: Receives either a higher dose of exidavnemab or placebo.

In addition to safety and tolerability as primary endpoints, researchers will assess a comprehensive set of biomarkers through plasma, cerebrospinal fluid (CSF) samples, and advanced digital measurements to gather detailed insights.

“We are very excited that the first patient with Parkinson’s disease has now been dosed in the EXIST Phase 2a study with exidavnemab,” said Gunilla Osswald, CEO at BioArctic. “It marks an important next step on BioArctic’s pioneering journey to broaden our research portfolio and help more patients and families with different neurological disorders to a better life.”

Recently, the results of two separate Phase 1 studies of exidavnemab, conducted in collaboration with AbbVie, were published in The Journal of Clinical Pharmacology. The results showed that exidavnemab is generally well-tolerated, with an excellent half-life of approximately 30 days. These data together with the high affinity and selectivity toward the pathological aggregated forms of α-synuclein, key to maintaining a high target binding in the brain, laid the foundation for the Phase 2a study.